Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

Po­ten­tial ap­provals keep emerg­ing out of Cel­gene’s old line­up.

To­day, the FDA ac­cept­ed and gave pri­or­i­ty re­view to CC-486, an acute myeloid leukemia drug that made a splash in De­cem­ber at ASH when Phase III da­ta showed pa­tients tak­ing the drug lived just un­der 10 months longer than pa­tients tak­ing place­bo, a ma­jor ad­vance in what has re­mained one of the most in­tractable blood can­cers.

The pri­or­i­ty re­view adds to the grow­ing body of ev­i­dence Bris­tol My­ers Squibb can point to in de­fense of their $74 bil­lion ac­qui­si­tion of Cel­gene, which at­tract­ed crit­i­cism not on­ly from con­sumer groups with an­ti-trust con­cerns but al­so from in­vestors who ques­tioned whether the thalido­mide-re­pur­pos­ing be­he­moth still had a deep enough pipeline to jus­ti­fy the cost.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.